+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

GATHER AND LISTEN 2026 – Request for Proposals

Gilead Sciences

Viral hepatitis and human immunodeficiency virus (HIV) remain major global health challenges, with overlapping risk factors, co-infection patterns, and barriers to care. Despite advancements, significant gaps persist in access to screening, linkage to treatment, integration of care models, and addressing gender-based disparities in healthcare. The World Health Organization (WHO) has set a goal to eliminate viral hepatitis and HIV as public health threats by 2030, but achieving this requires innovative, evidencebased interventions to ensure equitable healthcare delivery. Studies have shown that gender disparity exists in viral hepatitis care.1 Effective, gender-inclusive models must be developed and best practices for interventions replicated as part of a global commitment to achieve health equity. 2

To better understand key challenges at the intersection of viral hepatitis (HBV, HCV, HDV) and HIV prevention and treatment, Gilead is launching the 2026

GATHER AND LISTEN RFP, with a focus on health equity, gender disparities, and optimizing provider and system-level practices across virology. The GATHER AND LISTEN Request for Proposal (RFP) represents the merging of two previous initiatives – GATHER, which focused on integrating viral hepatitis and HIV care, and LISTEN, which aimed to advance gender-equitable healthcare strategies for viral hepatitis.

RFP Application Process

To apply for consideration for funding under the GATHER AND LISTEN RFP Program, you will need to submit an LOI* that is no longer than two pages, contains a concise overview of the proposed project and includes the total estimated budget. Applicants should submit the LOI application in the Gilead OPTICS portal.

How to Submit an LOI in Gilead OPTICS for the GATHER AND LISTEN RFP:

• Create an account, or login to your existing account in G. OPTICS

• Select “New Letter of Interest (LOI)”

• Select “GATHER AND LISTEN 2026” from the list of active RFPs

• Complete the required fields

• Submit the LOI Gilead will evaluate and rank all Letters of Interest (LOIs) received on a rolling basis until funds are exhausted.

• Submission window opens May 25, 2026, at 12:00 AM PST

• Submission window closes July 12, 2026, at 23:59 PM PST

AI Based Application Success Predictor

🔑 1. Strong Alignment with Gilead Therapeutic Areas (Top Predictor)

RSP supports research in:

HIV & viral hepatitis
Oncology (solid tumors)
Liver diseases

👉 Projects must clearly address unmet medical needs within these domains

🎯 2. High Scientific Merit + Innovation (Core Selection Criteria)

Proposals are evaluated on:

Scientific quality
Innovation
Feasibility

👉 Selection is made by independent expert scientific review committees

👉 Incremental or low-impact ideas are unlikely to be funded

🔄 3. Translational Relevance (Critical Differentiator)

Successful proposals typically:

Bridge basic → translational → clinical research
Address real-world clinical or biological gaps

👉 Even basic science must show clear relevance to disease outcomes

👩‍🔬 4. Early-Career Investigator Potential (Major Predictor)

The program specifically targets:

Junior faculty (within ~5 years of first appointment)

Evaluation includes:

Academic record
Publications
Research trajectory

👉 Strong “future leader” potential is essential

🤝 5. Strong Mentorship & Institutional Support

Mandatory requirement:
- Experienced mentor with proven track record
Evaluation includes:
- Mentoring plan quality
- Institutional resources

👉 Weak mentorship = frequent rejection

⏳ 6. Feasibility Within a 2-Year Timeline

Projects must:
- Be completed within ~2 years
- Produce outputs (papers, presentations)

👉 Overly ambitious or long-term projects are penalized

💰 7. Clear Scope for Moderate Funding

Typical award:
- ~$130K–$180K over 2 years

👉 Projects must be:

Focused
Deliverable within budget

🚫 8. Independence & Non-Product-Specific Research

Important distinction:
- Research should NOT directly evaluate Gilead products
- Must be independent and hypothesis-driven

👉 Unlike some pharma grants, this is not product-evaluation funding

🌍 9. Addressing Health Inequities & Global Impact

Strong preference for:
- Research addressing health disparities
- Global health (especially LMIC-focused programs)

👉 Increasingly important differentiator

📊 10. Potential for Career Advancement & Future Funding

Expected outcomes:
- Publications
- Follow-on grants
Program goal:
- Build independent investigators

👉 Think of RSP as career-launch funding

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with Gilead therapeutic areas
Scientific merit + innovation
Early-career investigator potential

Moderate predictors:
4. Translational relevance
5. Mentorship quality
6. Feasibility (2-year scope)

Supporting factors:
7. Institutional support
8. Health equity focus
9. Budget clarity

💡 Insider Insight

Compared to other pharma grants:

Gilead Sciences Research Scholars Program is:
👉 career-development focused (like NIH K awards)
👉 but industry-aligned in priority areas

👉 Key evaluation question:
“Is this a promising early-career researcher with a high-impact idea in a Gilead priority area?”

Specialties

Global Health

Others

Infectious Diseases

Eligibility Requirements

• Both investigator-initiated research (IIR) study proposals and Collaborative research study proposals (developed in conjunction with Gilead) will be considered (link to additional information on IIR vs Collaborative studies)

• This RFP does not aim to seek studies that focus on specific treatment outcomes. To the extent that treatments are used or measured as part of the proposed interventions, such treatments must have been approved by the relevant regulatory authorities and be commercially available. Gilead will not provide any medicinal product to conduct any research proposal related to this RFP

• Proposed research endpoints should be based on sound scientific hypotheses and generalizable across countries/regions

• Research proposals should include a comprehensive publication plan to present study results at scientific forums and to publish results in peer reviewed journals

• The proposed budget should be appropriately proportional with the study’s scope

• The proposed budget should include overhead costs and applicable taxes; overhead costs should not exceed 30% of the total budget

• The proposed study design should be feasibly executed within a reasonable timeframe proportional to the study’s follow-up duration

• There must be no more than one sponsor for contract negotiations and/or Institutional Review Board (IRB) review

• As the study sponsor, the Principal Investigator will be responsible for compliance with all laws and regulations applicable to research sponsors, including satisfying local requirements and obtaining all necessary regulatory and ethical approvals before beginning the study

Sponsor Details

Sponsor Institute/Organizations: Gilead Sciences

Sponsor Type: Corporate/Non-Profit

Address: 333 Lakeside Drive Foster City, CA 94404

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity